Targeting of NF-kappab signaling pathway, other signaling pathways and epigenetics in therapy of multiple myeloma

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F13%3A00010697" target="_blank" >RIV/00023736:_____/13:00010697 - isvavai.cz</a>

Result on the web

<a href="http://dx.doi.org/10.2174/1871529X11313010003" target="_blank" >http://dx.doi.org/10.2174/1871529X11313010003</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.2174/1871529X11313010003" target="_blank" >10.2174/1871529X11313010003</a>

Result language

angličtina

Original language name

Targeting of NF-kappab signaling pathway, other signaling pathways and epigenetics in therapy of multiple myeloma

Original language description

Multiple myeloma (MM) remains an incurable disease, at least for the big majority of patients, in spite of the great progress with new drugs in the last years. New treatment strategies are needed to improve the outcome of patients. At least, five proteasome inhibitors of the next generation with greater efficacy (carfilzomib, marizomib (salinosporamide A, NPI-0052), threonine boronic acid-derived proteasome inhibitor CEP-18770, the peptide-semicarbazone S-2209, the tripeptide mimetic BSc2118, and MLN9708/2238) have been recently tested in preclinical models of MM. Carfilzomib has been recently approved for the treatment of patients with MM who have received at least two prior therapies, including bortezomib and immunomodulatory derivatives (IMiDs, thalidomide, lenalidomide or pomalidomide).

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

<a href="/en/project/NT13836" target="_blank" >NT13836: The study of the myelodysplastic syndrome pathogenesis in patients with isolated del(5q) abnormality and the analysis of the effect of lenalidomide</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2013

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Cardiovascular & hematological disorders drug targets

ISSN

1871-529X

e-ISSN

—

Volume of the periodical

13

Issue of the periodical within the volume

1

Country of publishing house

NL - THE KINGDOM OF THE NETHERLANDS

Number of pages

18

Pages from-to

16-34

UT code for WoS article

—

EID of the result in the Scopus database

—